

X-Arrestin: a new retinal arrestin mapping to the X chromosome

Akira Murakami, Toshihiro Yajima, Hitoshi Sakuma, Margaret J. McLaren, George Inana*

Laboratory of Molecular Genetics, Bascom Palmer Eye Institute, University of Miami School of Medicine, 1638 NW 10th Avenue, Miami, FL 33136, USA

Received 2 September 1993; revised version received 21 September 1993

We have been using a differential cDNA cloning approach to isolate human retina-specific and retina-enriched genes [1]. A 1,314 bp cDNA was isolated by this approach, representing a highly retina-specific message encoding a 388 amino acid protein showing 58%, 50%, and 49% homology to bovine β -arrestin, and bovine and human retinal arrestin (S-antigen), respectively. Chromosomal mapping localized this new arrestin gene to the proximal long arm of the X chromosome, hence it was named X-arrestin. In situ hybridization demonstrated its expression in the inner and outer segments and the inner plexiform regions of the retina.

Arrestin; β -Arrestin; Retina; cDNA; X chromosome; Hybridization, in situ

1. INTRODUCTION

Isolation and characterization of retinal genes, such as rhodopsin [2], peripherin [3], cGMP-phosphodiesterase (the β subunit of which is the gene involved in a mouse model of retinal degeneration, the rd mouse) [4], arrestin (S-antigen) [5], α -transducin [6], phosducin [7], recoverin [1], cellular retinaldehyde binding protein [8], and interphotoreceptor retinol binding protein [9], have contributed greatly towards understanding retinal biology. A candidate gene approach using these genes (rhodopsin and peripherin) has led to the identification of the causative gene in some cases of autosomal dominant retinitis pigmentosa [10–12]. In an effort to further understand the biology of the human retina in normal and diseased states, we have been using a differential cDNA cloning approach to isolate human retina-specific and retina-enriched genes. This approach has already resulted in the isolation of the human recoverin cDNA and gene [1]. We report here the isolation of another retina-specific gene, arrestin, by this approach.

Retinal arrestin or S-antigen is a phototransduction protein found abundantly in the photoreceptors and thought to play a role in inactivation of light-activated rhodopsin [13,14]. S-Antigen is thought to quench the phototransduction cascade by binding to light-activated, phosphorylated rhodopsin, thereby blocking its interaction with transducin. S-Antigen is well conserved among species, and homologues have been isolated from cow, rat, human, and fruit fly [5,15–18]. Another type of arrestin, β -arrestin, has also been isolated and shown to specifically inactivate the β -adrenergic recep-

tor [19–21]. Thus, different types of arrestin mediate desensitization of specific receptors in signal transductions. The human arrestin we isolated is retina-specific in expression, homologous to β -arrestin and S-antigen but distinct from them, mapped to the X chromosome (hence named X-arrestin), and localized to the outer and inner segments and inner plexiform region of the retina.

2. MATERIALS AND METHODS

2.1. Preparation of retina-enriched cDNA library

A retina-enriched cDNA library was prepared as previously described [1]. Briefly, mRNA was isolated from the human retina, converted to double-stranded cDNA, subtracted with biotinylated fibroblast cDNA several times using streptavidin in combination with polymerase chain reaction (PCR) amplification, and cloned into pBluescript (Stratagene, La Jolla, CA). Approximately 300 recombinant clones were isolated. The present retina-specific clone was isolated in the initial analysis of 30 clones.

2.2. Northern blot analysis

Total human retinal, retinal pigment epithelium, and fibroblast RNA were isolated from tissue or cells using guanidine thiocyanate [22]. Human brain, liver, and lung RNA were obtained from Clontech (Palo Alto, CA). The RNA was electrophoresed in denaturing agarose gels [23], transferred onto nylon membranes by the Southern blotting method [24], and hybridized with a 32 P-labeled DNA probe. The hybridized blots were washed and autoradiographed as described before [25].

2.3. DNA sequencing

DNA was sequenced by the dideoxy chain termination method using the Sequenase DNA sequencing kit [26] (United States Biochemical, Cleveland, OH). Sequences were analyzed by the IntelliGenetics (Mountain View, CA) and Genetic Computer Group (Madison, WI) software packages.

2.4. Sublocalization of X-arrestin on the X chromosome

High-molecular weight genomic DNA from rodent-human somatic hybrids containing different segments of the human X chromosome

*Corresponding author. Fax: (1) (305) 326-6306.

(gift of Dr. T. Mohandas [27]) was digested with *EcoRI*, electrophoresed in 0.8% agarose gels, transferred onto nylon filters by the Southern method [24], and hybridized to ^{32}P -labeled cDNA probes. The hybridized filters were washed and autoradiographed as described [25]. The accuracy of the DNA panel was checked by the hybridization of a known X chromosome marker, TIMP (ATCC, Rockville, MD, [28]), to the blot which showed the correct localization to the Xp region (data not shown).

2.5. *In situ* hybridization

The whole eye (rat, human) was cut open, fixed in 4% paraformaldehyde, and immersed in 30% sucrose solution overnight. The tissue was frozen, sectioned, fixed again in 4% paraformaldehyde, treated with or without proteinase K, rinsed, and prehybridized in a mixture containing 50% formamide, 10% dextran sulfate, $1 \times$ Denhardt's mixture, and blocking tRNA. The probe was the sense (control) and antisense riboprobes prepared from a truncated X-arrestin Bluescript cDNA clone (1,130–1,314 bp at the 3' end) by transcription from either the T3 or T7 promoter with incorporation of [^{35}S]ribonucleotides (Stratagene). Hybridization was carried out overnight at 50°C, and the sample was treated with RNase A. The slides were washed with $0.1 \times \text{SSC}$ at 55–60°C and subjected to liquid emulsion autoradiography [29–32].

3. RESULTS AND DISCUSSION

A human retina-enriched cDNA library was prepared by repeated subtraction of a retina cDNA population with a biotinylated fibroblast cDNA population followed by amplification of the remaining clones by polymerase chain reaction [1]. Approximately 300 retina-specific or -enriched cDNA clones were obtained, and thirty were initially analyzed. Enrichment for retinal genes was confirmed by the identification of rhodopsin, α -transducin, cGMP-phosphodiesterase γ , and recoverin among the first ten cDNAs analyzed [33].

A cDNA clone was identified which showed a highly retina-specific pattern of expression on Northern analysis of RNA from human liver, lung, brain, fibroblast, retinal pigment epithelium, and neuroretina (Fig. 1). A single specie of 1.35 kb was observed. Sequence analysis of the clone revealed a nearly full-length 1,314 bp cDNA with a polyadenylation signal at position 1,269 and a poly(A) sequence at the 3' end (Fig. 2). An open reading frame began with an ATG codon at position 52, with a good consensus sequence for translation initiation codon [34], and ended with a termination codon at position 1,216, resulting in a protein of 388 amino acid residues and a calculated molecular mass of 42,864.

Comparison of the protein sequence with those in the Protein Information Resource sequence databank by the FastDB program (Intelligenetics Inc.) showed it to be most similar to arrestin, a protein involved in receptor-mediated homologous desensitization of retinal photoreceptors [13,14], and β -adrenergic receptors [19]. The highest homology was with bovine β -arrestin [19] at 58%, followed by rat β -arrestin 1 [20] at 57%, human thyroid arrestin (putative human β -arrestin) [21], and rat β -arrestin 2 [20] at 52%, bovine retinal and rat pineal arrestin (S-antigen) [15,16] at 50%, human retinal arrestin (S-antigen) [5] at 49%, and *Drosophila miranda*




Fig. 1. Northern blot analysis of human mRNA with the retinal cDNA probe. RNA from different human tissues are present in lanes 1–7: 1, lung; 2, liver; 3, brain; 4, retinal pigment epithelium; 5, neuroretina; 6 and 7, skin fibroblast. (A) Hybridized with ^{32}P -labeled cDNA clone; arrow points to the transcript of approximately 1.35 kb seen only in the retina. (B) Hybridized with the human β -actin probe to check on the quantity and quality of RNA present in each lane. Positions of the 28 S and 18 S ribosomal RNA and RNA standards are shown.

arrestin [35] at 37%. Despite the highest homology with the β -arrestins, the new arrestin (X-arrestin) seemed to be distinct from the β -arrestins in that the homology between X-arrestin and the β -arrestins (52–58%) was significantly lower than the homology among the human, rat, and bovine homologues of β -arrestin (74–99%) [20,21]. X-Arrestin was also clearly distinct from the original retinal arrestins (S-antigen) since it was only 49–50% homologous to them, while the homology among the retinal arrestins is over 80% [5,15,16]. Thus, the bovine β -arrestin, human thyroid arrestin (putative β), bovine and human retinal arrestin (S-antigen), and X-arrestin sequences were multiply aligned by the GENALIGN program (Intelligenetics Inc.) in order to closely examine the nature of the homologies (Fig. 3).

The homology among these arrestins existed throughout the sequence except for the carboxy-terminals. Divergence of the carboxy-terminal sequence in the arrestins has been noted previously [19,20]. Forty to sixty residues at the carboxy-termini of arrestins showed divergence, with the β -arrestins and the retinal arrestins

Fig. 2. Nucleotide and derived protein sequence of the retinal cDNA. The putative initiation methionine and termination codons are underlined. The translation yields a 388 amino acid protein. The polyadenylation signal at nucleotide 1,269 is overlined.

205

		D-G 1	
XARRESTIN	1	mskVFKKtSaNGKLsIYLGRDFVDHdVCEPIdCVVLVDPEYLKcRklfVnLTCAFryGRdDLvIGLTFRRDLyvt	
BOVARRB	1	MG dKGRVPKkaSPNGKLTvYLGKRDfVDHIdIVePVDGVVLVDPEYLKerVvYTLTCAFryGRdDLvIGLTFRRDL Pva	
HUMARRESTM	1	MGeKP GTRVPKkaSPNcKLTvYLGKRDfVDHIdKvDPVDGVVLVDPEYLKdRkVfVTLTCAFryGRdDLvIGLTFRRDL F1a	
BOVANTS	1	mKAnKPAPNHVIFKKISRDkSVTIYLGKRDYIDHLeVvPVDGVVLVDPELVKGRKvYvVLTCAFryGQEDIdVmGLSFRRL Yfs	
HUMRETSa	1	maasgKtsKsePNHVIFKKISRDkSVTIYLGKRDYIDHvsgVqPVDGVVLVDPELVKGRKvYvVLTCAFryGQEDvDvIGLTFRRDL Yfs	
consensus		maas--g-kp-p--vFKKIS-n-klTIYLGKRDfVDH-d-VePVDGVVLVDPEYLKgrkvYvLTCAFryGreDIdv-GLTFRRDLy-f-	
		2	
XARRESTIN	80	lqvvpaeasssqqaLTvLQERLlHKLGDnAYPFTlqmvNLPCSVTLQPGPEdAGKpCGIdFEVKaF CAENpEE tvaKRdyVRLVVRK	
BOVARRB	83	nvQsFPaPedkkPLTRLQERLlHKLGeHAYPFTFeIPnNLPCSVTLQPGPEDTGKACGVoyEVKAF CAENLEE KINKNSVRLVIRK	
HUMARRESTM	84	tyQaFPVPnpprPpTRLQERLlHKLGeHAYPFTFIPnNLPCSVTLQPGPEDTGKACGVDFEIrAF CAkLEE KsHKNSVRLVIRK	
BOVANTS	87	qvQVFPV GAsgatTRLQESLlHKLGeNTYFvLTFPDYLPcSVMLQAPQDvGKSCGVDFEIKAFATHSTdVEEDKIPKSSVRLIRK	
HUMRETSa	91	rQVvFPV GAastPtlQESLlHKLGeNTYFvLTFPDYLPcSVMLQAPQDvGKSCGVDFEIKAFATdSTdVEEDKIPKSSVRLIRK	
consensus		-qvqfpvpvg--g--TrLQERlHKLGe-nayPFTl-t-pdnLPCSVTLQPGPEdTGK-CGVDFEIKAFatca---EEEdki-Kr-sVRLVIRK	
		3	
XARRESTIN	168	VQfAPPeaGPpPaAqTIRfLlSaqPLQqAwMDrEvHYHGEPIsvNVaInNcTNKvIKKIKISvDQItDvVLYsldkYtkVfIqEftef	
BOVARRB	171	VQyAPePGQPcAETTRqFIMSDkPLHLEASLDKElYHGEPIsvNVHVTNNTNKTvKKIKISVRYADICLFntAQYKCPVameEaDDT	
HUMARRESTM	172	VQfAPePGQPcAETTRqFIMSDrLHLEASLDKElYHGEPIsvNVHVTNNTNKTvKKIKISVRYADICLFSTAQYKCPVaqIEqDDQ	
BOVANTS	177	IQHAPrdMGPOPRAEaSWQFFMSDKPLrLAVSLaKEIYHGEPIPVTVaVTNaTEKTvKKIKVIVEQVtNVVLYSSDYIKtVaaEEAQEK	
HUMRETSa	181	vQHAPleMGPOPRAEaSWQFFMSDKPLrLAVSLrEITYHGEPIPVTVtVTNaTEKTvKKIKaCvEQVaNvVLYSSDYIKpVameEAQEK	
consensus		vQ-APEe-GPQP-Aett-qF-mSdKpLHl-asldkEiyyHGEPI-VnVhvtNnt-KtvKKIK-sV-Q-advvLYs-d-YkKpVameEa-e-	
		4	
XARRESTIN	259	VAnSaFsqsfavTPILaascqKRGALDGLKHEDTNLASSTIIRpGmdkELLGILVSVYKvVnLaVScGGLCDLtaSDVgVELPlvLi	
BOVARRB	262	VAPSTFCkVYITlTPfLannREKRGALDGLKHEDTNLASSTIIReganrELIGILVSVYKvKVLVSRGGLDGLaSSVgVELPftLm	
HUMARRESTM	263	VsPSSTFCkVYITlTPfLsdnREKRGALDGLKHEDTNLASSTIIRKeganrELIGILVSVYKvKVLVSRGG dvasELpVlmhpkphdh	
BOVANTS	268	VPPNSsLTkTLTLVPLannRRRGIALDGKIKHEDTNLASSTIIRKGIhKtVmGILVSVYQIKVKL TVSGILGEL TSSEVATEVP	
HUMRETSa	272	VPPNstLTkTLTLPLannRRRGIALDGKIKHEDTNLASSTIIRKGIIdrTVIGILVSVYQIKVKL TVSGILGEL TSSEVATEVP	
consensus		V-pnStf-k--tlTPfLannREKRGIALDGKIKHEDTNLASSTIIRKGI--keVLIGILVSVY-vkVklVsrsggs-gg--eladvs-e--te-p	
		5	
XARRESTIN	350	HPKP sheaasssDIV iefstrkgeesqkavLaEGdeGSx	
BOVARRB	353	HPKPepphrEvpehftpvdtlnieldtndDDIVFEDFARlRKGMDKDeEEdgtGSprlndr	
HUMARRESTM	353	iPLPrPQsaPEtdvpvdtlniefdtnyatDDDIVFEDFARlRKGMDKdDyDqlc	
BOVANTS	353	FRLMHPQ PEDPdtAKESfQDeNfVFEFARhNLKAGSyKEktDqaamDEX	
HUMRETSa	357	FRLMHPQ PEDP AKESIQDANfVFEFARhNLKAGS aEEgkrdkndaDEX	
consensus		-plphqp---pedp--akes-qd-n-vf-e--div--d-----eqmkd-a-edex--gs-rlnr	

Fig. 3. Alignment of multiple arrestin sequences. The protein sequences of the new X-arrestin (XARRESTIN), bovine β -arrestin (BOVARRB), human thyroid arrestin (HUMARRESTM), bovine retinal arrestin (BOVANTS, S-antigen), and human retinal arrestin (HUMRETSa, S-antigen) were multiply aligned by the GENALIGN computer program (IntelliGenetics, Inc.). D-G and G/AXXXGK designate three regions showing homology to GTP phosphoryl binding sites, and the shadowed residues in the BOVANTS and HUMRETSa sequences are homologous to the pertussis toxin ADP-ribosylation site [5,39]. The regions designated 1-5 have been shown to be similar to transducin α in bovine β -arrestin [19].

Arrestin contains the three phosphoryl binding sites and regions 1 and 3 of the transducin α -like sequences. These sequences are common to all of the arrestins being compared, whereas regions 2 and 5 are present only in bovine β -arrestin and region 4 is common to bovine β -arrestin and the putative human homologue, thyroid arrestin. Notably, the ADP-ribosylation site is not present in X-arrestin or the bovine and human (thyroid) β -arrestins.

Chromosomal mapping of the X-arrestin gene by hybridization to panels of DNA from somatic cell hybrids containing specific human chromosomes (Oncor Inc., Gaithersburg, MD) (data not shown) and specific parts of the human X chromosome (Fig. 4) [27] localized the gene to Xcen-Xq21. Thus, X-arrestin joins the ranks of other retinal genes that have been localized to X, includ-

ing the red and green opsins, and the genes for choroideremia and Norrie disease [2,40-42]. Interestingly, a *Drosophila* arrestin in *D. miranda*, to which X-arrestin shows the highest homology (37%) among fly arrestins, has also been mapped to X [35]. This arrestin is a homologue of that described by LeVine et al. (Arr2) [43] and Yamada et al. [17], and is distinct from Arr1, a homologue of S-antigen [43]. An interesting functional study of Arr2 has been published recently [44], and its relevance to X-arrestin will be discussed later.

In situ hybridization analysis of X-arrestin using the rat and human retina demonstrated expression of this gene in the inner and outer segment and inner plexiform regions (Fig. 5). In view of the close homology among all the arrestins, the analysis was performed with a partial probe from the 3' end (1,130-1,314 bp) of the cDNA

representing the unique part of the X-arrestin sequence. A similar pattern of reaction in the photoreceptor cells, inner plexiform layer, and bipolar cells has been shown in a newt with antibodies against S-antigen [45]. The authors suggested that the reaction in the inner plexiform and bipolar cells may be due to arrestin related to β -adrenergic or similar chemical signal receptors.

The presence of up to four different arrestins has been reported [46]. The precise identity and function of X-arrestin needs to be determined. Which receptor signal transduction does it regulate? Its distinctness from S-antigen and β -adrenergic arrestin appears to be clear on the basis of the sequence differences and the uniqueness of the carboxy terminal region. It does not even appear to be a homologue of the third type of arrestin, represented by the rat β -arrestin 2 [20] since its homology to β -arrestin 2 is 52%, similar to β -arrestin 1 at 57%. Despite its slightly higher homology to β -arrestin, its expression pattern (retina-specific) is more like that of S-antigen than that of β -arrestin, which is expressed in multiple tissues [19]. Some of the in situ hybridization observed in the retinal inner and outer segments may represent cross-hybridization with S-antigen message (despite the use of a unique X-arrestin probe), but much of it most likely represents X-arrestin expression.

S-Antigen has been postulated to mimic transducin α and interact directly with photoactivated rhodopsin [5,13,14]. In this regard, the carboxy-terminal region including the ADP-ribosylation site has been considered to be important [47,48]. The dissimilarity of the carboxy-termini, including the lack of the ADP-ribosylation site in X-arrestin compared to S-antigen, appears to argue against identical functions for both, i.e. desensitization of rhodopsin signal transduction. Considering the sequence conservation between rhodopsin and color opsins [2], the involvement of X-arrestin in cone transduction also appears unlikely on the same grounds. The abundant pattern of in situ hybridization in the inner and outer segments also does not appear to support the presence of X-arrestin only in the cones. A recent report of *Drosophila* arrestin 2, however, is interesting in that, in addition to arrestin 1, which has been considered to be the homologue of S-antigen [17,18], it was also shown to be involved in the inactivation of rhodopsin [44]. The distribution of arrestin 2 in the fly retina was identical to that of arrestin 1, somewhat similar to the localization of X-arrestin to the inner and outer segments where S-antigen is present. Arrestin 2 is the homologue of *D. miranda* arrestin (98% homology), which showed the highest homology to X-arrestin among the fly arrestins and which also mapped to the X chromosomes [35]. Despite the species difference, the human X-arrestin may be functionally similar to the *Drosophila* arrestin 2, and may also be involved in inactivation of rhodopsin.

Alternatively, X-arrestin may play a role in an as yet




Fig. 4. Sublocalization of X-arrestin on the X chromosome. The hybridization of the X-arrestin probe to *Eco*RI-digested genomic DNA from rodent-human somatic hybrids containing different segments of the human X chromosome (gift of Dr. T. Mohandas) [27] is shown. The X segment contained in each hybrid is schematically shown at the top. The arrowheads point to the X-arrestin gene bands visible in some of the hybrid DNA and normal human genomic DNA (lane 6). The DNA size markers are *Hind*III-digested λ DNA.

undefined retina-specific signal transduction. In this respect, its expression in the inner plexiform region by in situ hybridization is especially interesting. β -Adrenergic transduction might be a possibility in the inner plexiform except we have shown that X-arrestin is distinct from β -arrestin. Cross-hybridization with β -arrestin message is a possibility, but use of the unique probe should have minimized it. The inner plexiform is where the bipolar, amacrine, and ganglion cells synapse, a site presumably of a variety of chemical signal transductions. X-Arrestin may be involved in one of these synaptic signal transductions that is highly retina-specific.

Recently, new α -G-proteins have been isolated that




Fig. 5. In situ hybridization of X-arrestin in the rat and human retina. The results of liquid emulsion autoradiography of the retina sections after hybridization with the X-arrestin sense or antisense riboprobes are shown. (A) Rat retina; (B) human retina. as, antisense; s, sense; GC, ganglion cell layer; IP, inner plexiform; IN, inner nuclear layer; OP, outer plexiform; ON, outer nuclear layer; IS, inner segment; OS, outer segment; PE, pigment epithelium.

lack the carboxyl ADP-ribosylation site and are insensitive to pertussis toxin [49,50]. These G-proteins are suggested to play a role in signal transductions involving receptor-mediated activation of phospholipase C, as is the case in invertebrate phototransduction [50]. Phospholipase C has been demonstrated in bovine rod outer segments (ROS) [51], and its activation by light has been shown in several species [51–53]. In fact, activation of bovine ROS phospholipase C by arrestin (assumed to be S-antigen) was recently reported [54]. In view of the absence of pertussis toxin ADP-ribosylation site in X-arrestin, it is interesting to speculate that X-arrestin may be involved in such a system. If true, X-arrestin may indeed be very similar functionally to the *Drosophila* arrestin 2 [44]. In vitro expression of the gene product and biochemical testing of such functions as quenching of opsin-mediated and β -adrenergic receptor-mediated

transduction, and activation of phospholipase C should help in identifying X-arrestin.

Note added in proof

Recent personal communication has indicated that Dr. C. Craft and colleagues may have isolated a similar arrestin.

Acknowledgements: Supported in part by Research to Prevent Blindness Inc. and National Retinitis Pigmentosa Foundation Inc.

REFERENCES

- [1] Murakami, A., Yajima, T. and Inana, G. (1992) *Biochem. Biophys. Res. Commun.* 187, 234–244.
- [2] Nathans, J., Thomas, D. and Hogness, D.S. (1986) *Science* 232, 193–202.
- [3] Travis, G.H., Brennan, M.B., Danielson, P.E., Kozak, C.A. and Sutcliffe, J.G. (1989) *Nature* 338, 70–73.

- [4] Bowes, C., Li, T., Danciger, M., Baxter, L.C., Applebury, M.L. and Farber, D.B. (1990) *Nature* 347, 677-680.
- [5] Yamaki, K., Tsuda, M. and Shinohara, T. (1988) *FEBS Lett.* 234, 39-43.
- [6] Lerea, C.L., Somer, D.E., Hurley, J.B., Klock, I.B. and Bunt-Milam, A.H. (1986) *Science* 234, 77.
- [7] Watanabe, Y., Kawasaki, K., Miki, N. and Kuo, C.-H. (1990) *Biochem. Biophys. Res. Commun.* 170, 951-956.
- [8] Crabb, J.W., Goldflam, S., Harris, S.E. and Saari, J.C. (1988) *J. Biol. Chem.* 263, 18688-18702.
- [9] Fong, S.-L. and Bridges, C.D.B. (1988) *J. Biol. Chem.* 263, 15330.
- [10] Dryja, T.P., McGee, T.L., Reichel, E., Hahn, L.B., Cowley, G.S., Yandell, D.W., Sandberg, M.A. and Berson, E.L. (1990) *Nature* 343, 364-366.
- [11] Farrar, G.J., Kenna, P., Jordan, S.A., Kumar-Singh, R., Humphries, M.M., Sharp, E.M., Sheils, D.M. and Humphries, P. (1991) *Nature* 354, 478-480.
- [12] Kajiwar, K., Hahn, L.B., Mukai, S., Travis, G.H. and Berson, E.L. (1991) *Nature* 354, 480-482.
- [13] Kuhn, H., Hall, S.W. and Wilden, U. (1984) *FEBS Lett.* 176, 473-478.
- [14] Wilden, U., Hall, S.C. and Kuhn, H. (1986) *Proc. Natl. Acad. Sci. USA* 83, 1174-1178.
- [15] Yamaki, K., Takahashi, Y., Sakuragi, S. and Matsubara, K. (1987) *Biochem. Biophys. Res. Commun.* 142, 904-910.
- [16] Abe, T., Yamaki, M., Tsuda, M., Singh, V.K., Suzuki, S., McKinnon, R., Klein, D.C., Donoso, L.A. and Shinohara, T. (1989) *FEBS Lett.* 247, 307-311.
- [17] Yamada, T., Takeuchi, Y., Komori, N., Kobayashi, H., Sakai, Y., Hotta, Y. and Matsumoto, H. (1990) *Science* 248, 483-486.
- [18] Smith, D.P., Shieh, B.-H. and Zuker, C.S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 1003-1007.
- [19] Lohse, M.J., Benovic, J.L., Codina, J., Caron, M.G. and Lefkowitz, R.J. (1990) *Science* 248, 1547-1550.
- [20] Attramadal, H., Arriza, J.L., Aoki, C., Dawson, T.M., Codina, J., Kwatra, M.M., Snyder, S.H., Caron, M.G. and Lefkowitz, R.J. (1992) *J. Biol. Chem.* 267, 17882-17890.
- [21] Rapoport, B., Kaufman, K.D. and Chazenbalk, G.D. (1992) *Mol. Cell Endocrinol.* 84, R39-R43.
- [22] Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rutter, W.J. (1979) *Biochemistry* 18, 5294-5299.
- [23] Lehrach, H., Diamond, D., Wozney, J.M. and Boedtker, H. (1977) *Biochemistry* 16, 4743-4751.
- [24] Southern, E.M. (1975) *J. Mol. Biol.* 98, 503-517.
- [25] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- [26] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463-5467.
- [27] Yen, P.H., Marsh, B., Mohandas, T.K. and Shapiro, L.J. (1984) *Somat. Cell Mol. Genet.* 10, 561-571.
- [28] Spurr, N.K., Goodfellow, P.N. and Docherty, A.J. (1987) *Ann. Hum. Genet.* 51, 189-194.
- [29] Wilcox, J.N., Roberts, J.L., Chronwall, B.M., Bishop, J.F. and O'Donohue, T. (1986) *J. Neurosci. Res.* 16, 89-96.
- [30] Treisman, J.E., Morabito, M.A. and Barnstable, C.J. (1988) *Mol. Cell. Biol.* 8, 1570-1579.
- [31] Linsenmayer, T.F., Gibney, E., Gordon, M.K., Marchant, J.K., Hayashi, M. and Fitch, J.M. (1990) *Invest. Ophthalmol. Vis. Sci.* 31, 1271-1276.
- [32] Ahmad, I. and Barnstable, C.J. (1993) *Exp. Eye Res.* 56, 51-62.
- [33] Murakami, A., Akaki, Y., Ara, F., Duval, E. and Inana, G. (1992) *Invest. Ophthalmol. Vis. Sci.* 33, 498A.
- [34] Kozak, M. (1987) *Nucleic Acids Res.* 15, 8125-8148.
- [35] Krishnan, R. and Ganguly, R. (1990) *Nucleic Acids Res.* 18, 5894.
- [36] Medynski, D.C., Sullivan, K., Smith, D., Van Dop, C., Chang, F.-H., Fung, B.K.-K., Seeburg, P.H. and Bourne, H.R. (1985) *Proc. Natl. Acad. Sci. USA* 82, 4311-4315.
- [37] Yatsunami, K. and Khorana, H.G. (1985) *Proc. Natl. Acad. Sci. USA* 82, 4316-4320.
- [38] Tanabe, T., Nukada, T., Nishikawa, Y., Sugimoto, K., Suzuki, H., Takahashi, H., Noda, M., Haga, T., Ichiyama, A., Kangawa, K., Minamino, N., Matsuo, H. and Numa, S. (1985) *Nature* 315, 242-245.
- [39] Wistow, G.J., Katial, A., Craft, C. and Shinohara, T. (1986) *FEBS Lett.* 196, 23-28.
- [40] Cremers, F.P.M., van den Pol, D.J.R., van Kerkhoff, L.P.M., Wieringa, B. and Ropers, H.H. (1990) *Nature* 347, 674-677.
- [41] Berger, W., Meindl, A., van de Pol, T.J.R., Cremers, F.P.M., Ropers, H.H., Doerner, C., Monaco, A., Bergen, A.A.B., Lebo, R., Warburg, M., Zergollern, L., Lorenz, B., Gal, A., Bleker-Wagemakers, E.M. and Meitinger, T. (1992) *Nature Genet.* 1, 199-203.
- [42] Chen, Z.-Y., Hendriks, R.W., Jobling, M.A., Powell, J.F., Breakerfield, X.O., Sims, K.B. and Craig, I.W. (1992) *Nature Genet.* 1, 204-208.
- [43] LeVine, H.III, Smith, D.P., Whitney, M., Malicki, D.M., Dolph, P.J., Smith, G.F.H., Burkhart, W. and Zuker, C.S. (1991) *Mechan. Dev.* 33, 19-26.
- [44] Dolph, R.J., Ranganathan, R., Colley, N.J., Hardy, R.W., Socolich, M. and Zuker, C.S. (1993) *Science* 260, 1910-1916.
- [45] Faure, J.-P. and Mirshahi, M. (1990) *Curr. Eye Res.* 9, 163-167.
- [46] Benovic, J.L., Bouvier, M., Caron, M.G. and Lefkowitz, R.J. (1988) *Annu. Rev. Cell Biol.* 4, 405-428.
- [47] Van Dop, C., Yamanaka, G., Steinberg, F., Sekura, R.D., Manclark, C.R., Stryer, L. and Bourne, H.R. (1984) *J. Biol. Chem.* 259, 23-26.
- [48] Palczewski, K., Buczylo, J., Imami, N.R., McDowell, J.H. and Hargrave, P.A. (1991) *J. Biol. Chem.* 266, 15334-15339.
- [49] Fong, H.K.W., Yoshimoto, K.K., Eversole-Cire, P. and Simon, M.I. (1988) *Proc. Natl. Acad. Sci. USA* 85, 3066-3070.
- [50] Strathmann, M. and Simon, M.I. (1990) *Proc. Natl. Acad. Sci. USA* 87, 9113-9117.
- [51] Ghalayini, A.J. and Anderson, R.E. (1984) *Biochem. Biophys. Res. Commun.* 124, 503-506.
- [52] Hayashi, F. and Amakawa, R. (1985) *Biochem. Biophys. Res. Commun.* 128, 954-959.
- [53] Millar, F.A., Fisher, S.C., Muir, C.A., Edwards, E. and Hawthorne, J.N. (1988) *Biochim. Biophys. Acta* 970, 205-211.
- [54] Ghalayini, A.J. and Anderson, R.E. (1992) *J. Biol. Chem.* 267, 17977-17982.

Volume 334/2, 1993

FEBSL 334 (2) 149-252

FEBS LETTERS

An international journal for the rapid
publication of short reports in
biochemistry, biophysics and molecular cell biology

EDITORS

H.R.V. Amstein, London, Book Reviews Editor
M. Baggiolini, Berne
J.E. Celis, Aarhus
U.-I. Flügge, Würzburg
S.P. Datta, London, Honorary Chairman
J.M. Gancedo, Madrid
B. Halliwell, London
J. Hanoune, Créteil
P.M. Harrison, Sheffield
M. Hatanaka, Kyoto
G. Hauska, Regensburg
H. Holzer, Freiburg i.Br.
Th.L. James, San Francisco
P. Jollès, Paris
C. Klee, Bethesda
N. Mantei, Zürich
P. Mathis, Saclay

A.D. Mirzabekov, Moscow
Sh. Mizushima, Tokyo
M. Montal, La Jolla
M.J. Owen, London
P.J. Randle, Oxford
T.A. Rapoport, Berlin-Buch
M. Saraste, Heidelberg, Reviews Editor
R. Sato, Osaka
G. Semenza, Zürich, Managing Editor
S. Shaltiel, Rehovot
V.P. Skulachev, Moscow
A.V. Somlyo, Charlottesville
G. Tettamanti, Milan
M. Van Montagu, Gent
G. Wagner, Boston
Sh. Yamamoto, Tokushima

Published by Elsevier Science Publishers B.V.
on behalf of the
Federation of European Biochemical Societies

FEBS LETTERS

An international journal established for the most rapid possible publication of essentially final short papers in the field of Biochemistry, Biophysics and Molecular Cell Biology

Published by Elsevier Science Publishers B.V. on behalf of the

FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

FEBS Letters is intended to be a journal for the fast dissemination of significant and novel work in an essentially complete form. It is NOT the vehicle for preliminary or fragmentary observations, or for 'leftovers' from larger papers, or for material which, although sound, does not have to appear quickly, or is addressed to a small audience only. As a rule, for example, we do not publish incomplete sequences, or sequences which are known in other species; or incomplete NMR or other spectroscopic assignments; or the conventionally achieved expression of a gene in bacteria or yeast; or just negative observations. Also, methodological papers are not usually published by us, unless they are truly novel and significant. The overriding criterion is that a paper must be of sufficient immediate importance to justify urgent publication.

Attention of the authors is drawn to the fact that our rejection procedure may take as long as in other journals, as explained elsewhere (see FEBS Letters, 217 (1987) 143-144. For details on the preparation of the manuscripts, see our 'Notes' (e.g. FEBS Letters, Volume 330, No. 3, pp. 352-353 and thereafter at the end of each tenth volume, i.e. at the end of Vol. 340, 350, 360, etc.).

The authors should submit their papers to the Editor who is the closest to their field of interest (rather than geographically): this accelerates the reviewing process. In case of doubt, please contact any editor. The 'date of receipt' eventually appearing in the published paper will be that upon which the editor who actually handled the manuscript took receipt of it. The authors must submit, if at all possible, a floppy disk of their manuscript (see under Notes to Authors). This accelerates the handling process and reduces the danger of misprints eventually appearing.

Note: telefax numbers are included below (in parentheses). *When corresponding with these editors it is preferable to use a courier service.

Editors:

G. SEMENZA (Managing Editor), Swiss Federal Institute of Technology, Department of Biochemistry, ETH-Zentrum, Universitätsstrasse 16, CH-8092 Zürich, Switzerland (41-1-252-8744)

S.P. DATTA (Honorary Chairman), London, England

M. SARASTE (Reviews Editor) EMBL, Meyerhofstrasse 1, Postfach 10.2209, D-69012 Heidelberg, Germany (49-6221-387306)

H.R.V. ARNSTEIN (Editor of book reviews only), London, England

M. BAGGIOLINI, Th. Kocher-Institut, Universität Bern, Freiestrasse 1, CH-3012 Berne, Switzerland (41-31-631-3799)

J.E. CELIS, Department of Medical Biochemistry, Ole Worms Allé, Building 170, University Park, Aarhus University, DK-8000 Aarhus, Denmark (45-86-131-160)

U.-J. FLÜGGE, Lehrstuhl Botanik I, Universität Würzburg, Mittlerer Dallenbergweg 64, D-97082 Würzburg, Germany (49-931-71446)

J.M. GANCEDO, Instituto de Investigaciones Biomédicas, CSIC, Calle Arturo Duperier 4, 28029 Madrid, Spain (34-1-585-4587)

B. HALLIWELL, Pharmacology Group, King's College, Chelsea Campus, Manresa Road, London SW3 6LX, England (44-71-333-4949)

J. HANOUNE, Unité de Recherches, INSERM U-99, Hôpital Henri Mondor, 94010 Créteil, France (33-1-48-98-09-08)

P.M. HARRISON, Department of Molecular Biology and Biotechnology, University of Sheffield, P.O. Box 594, Firth Court, Western Bank, Sheffield, S10 2UH, England (44-742-728-697)

M. HATANAKA, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-01, Japan (81-75-761-5626)

G. HAUSKA, Universität Regensburg, Lehrstuhl für Zellbiologie und Pflanzenphysiologie, Universitätsstrasse 31, Postfach 397, D-93040 Regensburg 31, Germany (49-941-943-3352) (till Dec. 31st 1993)

H. HOLZER, Biochemisches Institut der Universität, Hermann-Herder-Str. 7, D-79104 Freiburg i.Br., Germany (49-761-203-3331)

Th.L. JAMES, UCSF Magnetic Resonance Laboratory, Department of Pharmaceutical Chemistry, 926 Medical Science, San Francisco, CA 94143-0446, USA (1-415-476-0688) (from Jan. 1st, 1994)

P. JOLLÈS, Laboratory of Proteins/Enzymes/Glycoconjugates, CNRS/Université de Paris V, 45, rue des Saint-Pères, F 75270 Paris Cedex 06, France (33-1-4015-9296)

C. KLEE, NIH, National Cancer Institute, Laboratory of Biochemistry, Bldg. 37, Room 4E-28, Bethesda, MD 20892, USA (1-301-402-3095)

N. MANTEI, Neurobiologie, ETH-Hönggerberg, CH-8093 Zürich, Switzerland (41-1-371 0235)

P. MATHIS, Dept. de Biologie Moléculaire et Cellulaire, Section de Bioénergétique, Bat. 532, C.E. Saclay, F 91191 Gif-sur-Yvette, France (33-1-69-08-87-17)

A.D. MIRZABEKOV, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov str. 32, 117984 Moscow B-334, Russia* (7-095-135-1405)

Sh. MIZUSHIMA, Tokyo College of Pharmacy, 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan (81-426-77 7497)

M. MONTAL, Department of Biology, Science Building, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA (1-619-534 0931)

M.J. OWEN, Imperial Cancer Research Fund, PO Box 123, 44 Lincoln's Inn Fields, London WC2A 3PX, England (44-71-269-3479)

P.J. RANDLE, Nuffield Department of Clinical Biochemistry, Radcliffe Infirmary, Woodstock Rd., Oxford OX2 6HE, England (44-865-224 000)

T.A. RAPOPORT, Max-Delbrück-Zentrum für molekulare Medizin, Robert Rössle-Strasse 10, D-13122 Berlin-Buch, Germany (49-30-949-4161)

R. SATO, Osaka University, Institute for Protein Research, 3-2 Yamadaoka, Suita, Osaka 565, Japan (81-6-876-2533) (until Dec. 31st, 1993)

S. SHALITEL, The Weizmann Institute of Science, Rehovot 76100, Israel (972-8-465-488)

V.P. SKULACHEV, A.N. Belozersky Laboratory of Molecular Biology and Bioorganic Chemistry, Moscow State University, 119899 Moscow, Russia* (7-095-939-0338)

A.V. SOMLYO, Department of Molecular Physiology and Biological Physics, Box 449, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, VA 22908, USA (1-804-982-1616)

G. TETTAMANTI, Università degli Studi di Milano, Facoltà di Medicina e Chirurgia, Dipartimento di Chimica e Biochimica Medica, Via Saldini, 50, I 20133 Milano, Italy (39-2-236-3584)

M. VAN MONTAGU, Laboratorium voor Genetika, Universiteit Gent, Ledeganckstraat 35, B-9000 Gent, Belgium (32-9-264-5349)

G. WAGNER, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA (1-617-432-4383) (until Dec. 31st, 1993)

Sh. YAMAMOTO, Department of Biochemistry, Tokushima University School of Medicine, Kuramoto-cho, Tokushima 770, Japan (81-886-33-6409) (from Jan. 1st, 1994)

Published weekly.

This journal is printed on acid-free paper

Printed in The Netherlands.

Elsevier Science Publishers B.V., PO Box 211, 1000 AE Amsterdam, The Netherlands

The exclusive © for all languages and countries is vested in the Federation of European Biochemical Societies

*No part of this volume may be reproduced in any form by print, photoprint, microfilm or any other means without the prior permission of the copyright owner**

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for readers in the U.S.A.

This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1981 may be copied for a per-copy fee of US \$ 2.25, also payable through the Center. (N.B. For review journals this fee is \$ 0.25 per copy per page.) This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors

Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Federation of European Biochemical Societies. This transfer will ensure the widest possible dissemination of information

ADONIS Identifier

This Journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

* But see item 6 in Notes to Authors

This journal is printed on acid-free paper

PRINTED IN THE NETHERLANDS

Subscription information: The subscription price for 1993, volumes 315-335 (21 volumes in 63 issues) is / 5586.00 (US\$ 3192.00) including postage, packaging and handling.

The Dutch guilder price is definitive. The U.S. dollar price is subject to exchange-rate fluctuations and is given only as a guide. Subscriptions are accepted on a prepaid basis only, unless different terms have been previously agreed upon.

Subscription orders can be entered only by calendar year (Jan-Dec.) and should be sent to Elsevier Science Publishers, Journal Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, telephone 31.20.5803642, fax 31.20.5803266, or to your usual subscription agent.

Postage & handling charges include surface delivery except following countries where air delivery via SAL (Surface Air Lift) mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA.

Claims for missing issues must be made within six months of our publication (mailing) date, otherwise such claims cannot be honoured free of charge.

The Publishers reserve the right to issue additional volumes during the course of the year. Such volumes will be invoiced before publication and delivered on receipt of payment. In the United States and Canada: For further information concerning this or any other Elsevier Science Publishers journal, contact Elsevier Science Publishing Co., Inc., Attn: Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, USA. Telephone: (212) 633-3750; Telefax: (212) 633-3990; Telex: 420-643 AEP UL.

Information for Advertisers. Advertising orders and enquiries can be sent to the Advertising Manager, Elsevier Science Publishers, Advertising Department, Van de Sande, Bakhuyzenstraat 4, 1061 AG Amsterdam, or P.O. Box 211, 1000 AE Amsterdam, The Netherlands, Tel.: 20-5153.220; Fax: 20-6833.041, attn. Advertising Dept; U.K.: T.G. Scott and Son Ltd., Tim Blake, Portland House, 21 Narborough Road, Cosby, Leicestershire, LE9 5TA, U.K., Tel.: (44) (533) 753.333; Fax: (44) (533) 750.522; U.S.A. and Canada: Weston Media Associates, Daniel Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110, U.S.A., Tel.: 203-261.2500; Fax: 203-261.0101